Blend and naming
I hear a settled formulation in the Wolverine name, and the combination evidence cannot support that impression. “Wolverine peptide stack” means the BPC-157 and TB-500 pairing; the name supplies neither a validated formulation nor a clinical ratio.
What is the difference between BPC-157 and TB-500?
BPC-157 is a synthetic 15-amino-acid peptide derived from a gastric-juice protein. TB-500 is the Ac-LKKTETQ fragment of thymosin beta-4, with 7 residues taken from the 43-residue parent. They have different origins, sizes and proposed roles in repair.
Does the Wolverine stack have proven synergy?
No controlled combination study establishes an advantage from combining them. The BPC-157 systematic review contained no TB-500 combination work; the rationale extrapolates from separate mechanisms.
Injury and safety
The leap from animal injury to human recovery bothers me most. The difference survives even when the underlying experiment is impressive.
Does BPC-157 TB-500 help tendon or muscle injuries?
BPC-157 improved transected Achilles repair in rats and has rat quadriceps-reattachment research. The blend's effect on human injury recovery is unproven.
What side effects have people reported?
Anecdotal accounts include local irritation, fatigue, lightheadedness, headache, nausea, dizziness, anxiety, insomnia, palpitations and mood changes. They cannot establish causation or event rates. The effects page places those accounts beside the clinical and preclinical cautions.
Does TB-500 cause cancer?
The thymosin beta-4 tumor-model and cell-line research creates a theoretical concern involving metastasis and angiogenesis. It demonstrates no cancer outcome in human blend users. Long-term combination safety remains uncharacterized.
Dose, spray and oral formats
Those animal doses and an unverified combined mass leave the human regimen unresolved. None of the delivery-format names repairs that gap.
Is there a validated BPC-157 TB-500 dosage or cycle?
No validated human dose, ratio, cycle or loading-and-maintenance schedule exists for the blend. A full-length thymosin beta-4 rat stroke experiment even found a non-monotonic response, with the highest dose giving no benefit. It supplies no human regimen.
Do oral products or Wolverine spray have human trial support?
There is no controlled human combination trial establishing absorption, effectiveness or safety for those formats. BPC-157's peroral animal research cannot validate an oral BPC-157 TB-500 blend.
What is the half-life?
The pharmacokinetic reference summary records under 30 minutes for BPC-157 in rats and dogs. Human half-life at research-use doses is unvalidated for both constituents and for the combination.
Approval and WADA
I separate these questions because a change to a compounding category and a sport prohibition answer different problems.
Are BPC-157 and TB-500 FDA-approved?
Neither component is FDA-approved for human use; the blend has no approved indication. On FDA's page current as of April 22, 2026, both nominations are withdrawn and neither remains in Category 2. FDA has not explained the compounding implications.
Did the July 2026 advisory meeting approve them?
The July 23-24 PCAC agenda considered them for the 503A Bulks List after FDA staff proposed against listing. Advisory review supplies no final FDA listing decision. As of September 2026, FDA had published no vote record.
Are both constituents prohibited in sport?
Yes. WADA prohibits BPC-157 and thymosin beta-4/TB-500 under the relevant non-approved-substance and peptide/growth-factor categories, in and out of competition.